Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

LRRK2 antibody (AA 930-961)

LRRK2 Reactivity: Human, Mouse WB, IF Host: Rabbit Polyclonal RB07209 unconjugated
Catalog No. ABIN391148
  • Target See all LRRK2 Antibodies
    LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))
    Binding Specificity
    • 5
    • 4
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 930-961
    Reactivity
    • 20
    • 7
    • 1
    Human, Mouse
    Host
    • 17
    • 3
    Rabbit
    Clonality
    • 16
    • 4
    Polyclonal
    Conjugate
    • 17
    • 1
    • 1
    • 1
    This LRRK2 antibody is un-conjugated
    Application
    • 14
    • 9
    • 8
    • 4
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunofluorescence (IF)
    Purification
    This antibody is purified through a protein A column, followed by peptide affinity purification.
    Immunogen
    This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 930-961 amino acids from human PARK8(LRRK2).
    Clone
    RB07209
    Isotype
    Ig Fraction
    Top Product
    Discover our top product LRRK2 Primary Antibody
  • Application Notes
    IF: 1:10~50. WB: 1:1000. WB: 1:1000
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
    Expiry Date
    6 months
  • Huang, Song, Murphy, Holton, Lashley, Revesz, Gai, Halliday: "LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions." in: Acta neuropathologica, Vol. 116, Issue 6, pp. 639-46, (2009) (PubMed).

    Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

  • Target
    LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))
    Alternative Name
    PARK8 (LRRK2) (LRRK2 Products)
    Synonyms
    LRRK2 antibody, AURA17 antibody, DARDARIN antibody, PARK8 antibody, RIPK7 antibody, ROCO2 antibody, 4921513O20Rik antibody, 9330188B09Rik antibody, AW561911 antibody, D630001M17Rik antibody, Gm927 antibody, cI-46 antibody, leucine-rich repeat kinase 2 antibody, leucine rich repeat kinase 2 antibody, lrrk2 antibody, LRRK2 antibody, Lrrk2 antibody
    Background
    Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.
    Molecular Weight
    286103
    Gene ID
    120892
    NCBI Accession
    NP_940980
    UniProt
    Q5S007
    Pathways
    Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development
You are here:
Support